Page last updated: 2024-11-06

synthalin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Synthalin A is a guanidine derivative that was initially synthesized in the early 20th century as a potential treatment for diabetes. It was discovered by the German chemist, Franz Frank, in 1922. The compound exhibits hypoglycemic activity by inhibiting glucose uptake in the liver. However, its use was discontinued due to significant side effects such as liver damage and cardiovascular complications. Research interest in Synthalin A has been renewed in recent years due to its potential as a starting point for the development of new antidiabetic drugs with improved safety profiles. Studies are investigating the structure-activity relationships of Synthalin A analogs to identify derivatives with enhanced hypoglycemic activity and reduced toxicity.'

synthalin A: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

synthalin : A hydrochloride resulting from the reaction of decamethylenediguanidine with 2 mol eq. of hydrogen chloride. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

synthalin A : A member of the class of guanidines that is decane having guanidino groups at the 1- and 10-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID66977
CHEMBL ID1194310
CHEBI ID84338
SCHEMBL ID336302
MeSH IDM0047497

Synonyms (33)

Synonym
CHEMBL1194310
chebi:84338 ,
NCGC00024699-01
tocris-0635
synthalin
synthalin a
anticoman
BPBIO1_001182
BIOMOL-NT_000185
NCGC00024699-02
2-[10-(diaminomethylideneamino)decyl]guanidine
111-23-9
1,1'-decane-1,10-diyldiguanidine
n,n'''-1,10-decanediylbisguanidine
unii-zea6y34xyt
zea6y34xyt ,
einecs 203-848-1
1,10-diguanidinodecane
SCHEMBL336302
1-(10-guanidinodecyl)guanidine
decamethylenediguanidine
decamethylenebis(guanidine)
1,1'-decamethylenediguanidine
1,10-bis(guanidino)decane
AKOS024458591
n,n'-decane-1,10-diyldiguanidine
DTXSID50911935
Q7662695
1,1-decamethylenediguanidine
guanidine, 1,1-decamethylenedi-
bis-g-10
n,n-1,10-decanediylbis(guanidine)
guanidine, n,n-1,10-decanediylbis-

Research Excerpts

Overview

Synthalin A is a guanidine derivative, chemically related to the antidiabetic drugs of the biguanide group.

ExcerptReferenceRelevance
"Synthalin A is a guanidine derivative, chemically related to the antidiabetic drugs of the biguanide group. "( Effects of the biguanide synthalin A on the pancreatic A2-cell of the guinea pig.
Ostenson, CG, 1983
)
2.01

Dosage Studied

ExcerptRelevanceReference
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
hepatotoxic agentA role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.
hypoglycemic agentA drug which lowers the blood glucose level.
nephrotoxinA poison that interferes with the function of the kidneys.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency89.12510.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency23.10250.000811.382244.6684AID686978; AID686979
survival motor neuron protein isoform dHomo sapiens (human)Potency14.12540.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1130854Binding affinity to DNA (unknown origin) assessed as decrease in velocity of L1210 DNA-dependent DNA polymerase reaction1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Potential antitumor agents. 31. Quantitative structure-activity relationships for the antileukemic bis(guanylhydrazones).
AID1130852Anti-leukemic activity against mouse L1210 cells allografted in ip dosed DBA2 mouse assessed as increase in host lifespan administered qd for 1 to 4 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Potential antitumor agents. 31. Quantitative structure-activity relationships for the antileukemic bis(guanylhydrazones).
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1130853Anti-leukemic activity against mouse L1210 cells allografted in ip dosed DBA2 mouse assessed as optimum drug dose required for the effect administered qd for 1 to 4 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Potential antitumor agents. 31. Quantitative structure-activity relationships for the antileukemic bis(guanylhydrazones).
AID540235Phospholipidosis-negative literature compound
AID1130855Displacement of ethidium from poly[d(A-T)]-poly[d(A-T)] DNA (unknown origin) by fluorimetric assay1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Potential antitumor agents. 31. Quantitative structure-activity relationships for the antileukemic bis(guanylhydrazones).
AID1130856Displacement of ethidium from poly[d(G-C)]-poly[d(G-C)] DNA (unknown origin) by fluorimetric assay1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Potential antitumor agents. 31. Quantitative structure-activity relationships for the antileukemic bis(guanylhydrazones).
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (53.57)18.7374
1990's5 (17.86)18.2507
2000's3 (10.71)29.6817
2010's2 (7.14)24.3611
2020's3 (10.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.42 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]